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Abstract
Background Immunotherapeutic treatments targeting
amyloid-β plaques in Alzheimer’s disease (AD) are associated
with the presence of amyloid-related imaging abnormalities with
oedema or effusion (ARIA-E), whose detection and classifica-
tion is crucial to evaluate subjects enrolled in clinical trials.
Purpose To investigate the applicability of subtractionMRI in
the ARIA-E detection using an established ARIA-E-rating
scale.
Methods We included 75 AD patients receiving bapineuzumab
treatment, including 29 ARIA-E cases. Five neuroradiologists
rated their brain MRI-scans with and without subtraction im-
ages. The accuracy of evaluating the presence of ARIA-E,
intraclass correlation coefficient (ICC) and specific agreement
was calculated.
Results Subtraction resulted in higher sensitivity (0.966) and
lower specificity (0.970) than native images (0.959, 0.991, re-
spectively). Individual rater detection was excellent. ICC scores
ranged from excellent to good, except for gyral swelling (mod-
erate). Excellent negative and good positive specific agreement
among all ARIA-E imaging features was reported in both
groups. Combining sulcal hyperintensity and gyral swelling sig-
nificantly increased positive agreement for subtraction images.
Conclusion Subtraction MRI has potential as a visual aid in-
creasing the sensitivity of ARIA-E assessment. However, in
order to improve its usefulness isotropic acquisition and
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enhanced training are required. The ARIA-E rating scale may
benefit from combining sulcal hyperintensity and swelling.
Key Points
• Subtraction technique can improve detection amyloid-
related imaging-abnormalities with edema/effusion in
Alzheimer’s patients.
• The value of ARIA-E detection, classification and monitor-
ing using subtraction was assessed.
• Validation of an established ARIA-E rating scale, recom-
mendations for improvement are reported.
• Complementary statistical methods were employed to mea-
sure accuracy, inter-rater-reliability and specific agreement.
Keywords Alzheimer's disease (AD) . Amyloid beta (Aβ) .
Immunotherapy . ARIA (amyloid-related imaging
abnormalities) . MRI (magnetic resonance imaging)
Abbreviations
AD Alzheimer’s disease
ARIA Amyloid-related image abnormalities
ARIA-E Amyloid-related image
abnormalities with vasogenic
oedema and/or sulcal effusion
ARIA-H Amyloid-related image abnormalities
with hemosiderin deposits
and microbleeds
Aß Amyloid-ß
CSF Cerebrospinal fluid
FLAIR Fluid-attenuated inversion recovery
FLIRT FMRIB’s linear image registration tool
ICC Intraclass correlation coefficient
IRR Inter-rater reliability
MMSE Mini-Mental-State-Examination
MRI Magnetic resonance imaging
NAT Native FLAIR images
(baseline and follow-up)
PH Parenchymal hyperintensity
SH Sulcal hyperintensity
SUB Subtraction images
SW Gyral swelling
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease defined by the deposition of amyloid-ß (Aß) plaques
and τ-neurofibrillary tangles in the brain, leading to cognitive
impairment and neuronal loss [1, 2]. To date, despite multiple
investigated treatment approaches, no curative options exist.
Aβ is a promising target for immunotherapy, and both active
and passive immunisation strategies aiming at removal of Aß-
plaques and prevention of neurodegeneration are currently
being evaluated in a number of trials [3–6].
Amyloid-related image abnormalities (ARIA) were reported
on brain MRI of AD subjects enrolled in immunisation trials
and they are likely related to the clearance mechanism of Aβ
[7]. Clinically, ARIA cases can be associated with non-specific
signs and symptoms and reduction in cognitive performance as
assessed by the Mini-Mental-State-Examination (MMSE),
though most cases remain asymptomatic [8–13]. Based on their
radiological appearance, these abnormalities are subdivided into
ARIA-H, representing hemosiderin deposits and microbleeds in
the brain parenchyma resulting from blood leakage from adja-
cent brain vessels, and ARIA-E, showing parenchymal
vasogenic oedema and/or sulcal effusion [7]. Considering the
variety of pathologies with similar radiological appearances, the
risk of misidentification and misinterpretation of ARIA-E ab-
normalities is significant and may affect patients’ monitoring
and eventually the outcome of clinical trials [14].
A visual rating scale allowing an easily applicable charac-
terisation of ARIA-E in all brain regions was developed to
estimate the severity of these abnormalities [4]. Bechten
et al. recently demonstrated that this rating scale was simple
and robust and showed a high agreement both in the identifi-
cation and determination of ARIA-E severity and in the re-
gional categorisation of the various manifestations [15]. In
order to improve the classification of ARIA cases and scoring
we explored the applicability of adding subtraction images.
The subtraction technique, in which one scan is digitally
subtracted from a co-registered second scan, has already prov-
en to be valuable in the detection, quantification and monitor-
ing of lesions over time in the setting of multiple sclerosis and
glioblastoma multiforme. In both the latter disorders, the ef-
fect of repositioning and enhancing contrast between the ac-
tive lesions and the non-active background must be taken into
account [16–19]. The aim of this study was to assess the value
of using registered subtraction images (1) for detection and (2)
classification of ARIA-E, and (3) to determine the inter-rater
agreement using an established ARIA-E rating scale.
Methods
Patient group and study design
We included 75 subjects with AD from a phase II, multicentre,
randomised, double-blind, placebo-controlled multiple ascending
dose study of bapineuzumab, a humanised monoclonal antibody
targeting Aβ [20]. The phase II multicentre study was performed
at 30 different sites in the USA between April 2005 and
March 2008. 234 patients were randomly assigned to receive
intravenous bapineuzumab or a placebo, in a ratio of 8:7, in one
of four sequential dose cohorts. Volumetric and safety baseline
and follow-up fluid-attenuated inversion recovery (FLAIR) MRI
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scans were performed prior to first infusion and 6 weeks after
treatment, respectively, and then patients were scanned subse-
quently at intervals of 13 weeks up to week 71 [20].
For the current study we assessed 75 AD patients from the
above-described multicentre study, including 29 positive
ARIA-E and 46 negative ARIA-E cases. Follow-up scans
were obtained at regular intervals. For positive ARIA-E cases
we selected the first scan on which the ARIA-E was seen and
compared this with the baseline scan. Table 1 shows the base-
line subject characteristics.
MRI and subtraction images
Each patient underwent a baseline MRI including an axial
FLAIR sequence before treatment and follow-up scans at
scheduled intervals. At each site, MRIs were performed with
identical parameters. However, among sites the scanning pro-
tocols differed slightly. Mean echo time (TE) was 129.6 ms
(interpatient range 79–159.5 ms); mean repetition time (TR)
9,374.8 ms (range 9,002–11,002 ms); flip angle (90, 150 or
180). The voxel size was 0.51x0.51 mm, 0.88x0.88 mm,
0.90x0.90 mm, 0.94x0.94 mm or 1.02x1.02 mm; slice thick-
ness 5 mm. Axial T2-weighted and FLAIR sequences were
anonymised. FLAIR images were used to generate subtraction
images. T2-weighted images were not employed because the
high signal intensities due to partial volume averaging effects
from adjacent blood or CSF could mimic parenchymal lesions
and cause artefacts [19–21]. The follow-up images were
registered to baseline images through an automatic voxel-
based registration algorithm relying on mutual information
as the matching criterion [22, 23]. Linear intra- and intermodal
brain image registration were obtained through FSL Flirt soft-
ware program and trilinear interpolation was employed for
both image interpolation and reslicing of data [21, 24, 25].
First a global scaling was applied based on the ratio of
the average brain signal intensity (based on FSL BET) of
the baseline and follow-up images (native images; NAT)
[26]. Then the baseline scan (Fig. 1a) was registered to the
follow-up scan (Fig. 1b) resulting in a new registered base-
line scan (Fig. 1c). The registered baseline scan was
subtracted from the follow-up scan accordingly. This re-
sulted in the pixel-enhanced subtraction image (subtrac-
tion images; SUB) (Fig. 1d), highlighting changes in time.
Image analysis
Five experienced neuroradiologists independently reviewed
the scans of the 75 subjects included. Reading results of the
scans of the phase II bapineuzumab study were used as gold
standard for ARIA-E cases, which had been performed previ-
ously by two neuroradiologists independently (kappa=0.76)
followed by consensus reached over all FLAIR MRIs from
the 262 patients [7]. The raters were blinded to clinical infor-
mation and unaware of the gold standard ARIA-E rating
scores. Prior to scoring, the neuroradiologists were provided
a web-based introduction regarding ARIA-E and a training set
on how to use the rating scale. The scans were presented in
randomorder to the nheuroradiologists on aweb platform, which
allowed the raters to compare the NAT and SUB, to perform
measurements and to score each case. Each rater was requested
to identify ARIA-E using baseline and follow-up axial FLAIR
MR images without the use of the SUB. Twelvemonths later, the
scans of the same subjects were presented in a new random order
to the same raters, who re-evaluated them with the use of the
subtraction MRI as an additional tool.
ARIA-E rating scale
Table 2 reports the rating scale for ARIA-E [4]. For
hyperintensities or gyral swelling, ratings are performed ac-
cording to the anatomical location in terms of lobe and side
(L/R), resulting in scores for six regions bilaterally: frontal,
parietal, temporal and occipital lobes, central region (includ-
ing basal ganglia, thalamus, internal and external capsules,
corpus callosum and insula) and infratentorial region
(brainstem and cerebellum). Within each region, the score
depends on the spatial extent and multifocality of the abnor-
mality. In the case of abnormalities involving multiple loca-
tions, their maximum in-plane diameter in each lobe is mea-
sured and scored. The regional scores on each side of the brain
(L/R) are summed up for each ARIA-E subtype and the
Table 1 Demographics and baseline information of the Alzheimer’s
disease (AD) patients included in this study
AD subjects No. %
Total 75 100
Female 46 61.3
Male 29 38.7
In initial study 8 Mean SD
Age (y) 67.36 8.35
Baseline MMSE* 20.83 2.92
Baseline DAD** 86.27 14.45
ApoE allele frequency
0 16 21.92
1 37 50.68
2 20 27.40
Assigned dose in mg/kg
0.15 13 17.33
0.5 17 22.67
1 23 30.67
2 22 29.33
MMSE Mini Mental State Examination, DAD Disability Assessment for
Dementia
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highest score of the 3 ARIA-E imaging features subtypes con-
tributed to the score of the region.
Statistical analysis
The sensitivity and specificity of ARIA-E detection with NAT
alone and with SUB were measured. In this study, the gold
standard true-positives were the cases determined to have
ARIA-E lesions by consensus after conducting the inter-rater
reliability study [7] before using SUB. This is a conservative
approach since some false-negatives based on subtractionmay
be real ARIA-E.We evaluated the number of ARIA-E cases in
which ≥1 neuroradiologist(s) rated a score of ≥1 in at least one
brain region. Moreover, a majority vote, i.e. the number of
cases in which at least three of the five raters rated a score of
≥1 in one or more brain regions, was assessed.
Observer variation was quantified in absolute terms
through agreement and in relative terms through reliability
[27]. The interobserver reliability, i.e. the consistency among
the scores of the five raters, was assessed by determining the
Fig. 1 Three different cases of amyloid-related image abnormalities with
vasogenic oedema and/or sulcal effusion (ARIA-E). Baseline and follow-
up axial FLAIR scans (vertical section A and B, respectively) showing
multiple lesions. Section C illustrates the registration image of the follow-
up scan to the baseline scan. Section D shows the subtraction image
aiding in the detection, distinguishing or exclusion of ARIA-E findings.
(1) Signal hyperintensities (especially on the right hemisphere) are visible
on the follow-up FLAIR axial image. The generated subtraction image
helps in differentiating between parenchymal and sulcal hyperintensities.
Note subtraction artefacts in the ventricles due to poor CSF suppression.
(2) Subtle ARIA-E abnormalities are barely visible on FLAIR scan but
can be more easily detectable on subtraction images (arrows). (3) Gyral
swelling is hardly detectable at axial FLAIR but it is clearly distinguish-
able in the subtraction image (arrows). Note that the slice angulation
between baseline and follow-up is quite different, but the registered base-
line is nevertheless relative comparable to the follow-up
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intraclass correlation coefficient (ICC). This was calculated as
the ratio between subject variability and total variability, and a
two-way mixed model measuring the absolute agreement was
chosen because of the skewed scores distribution in a fixed
ordinal scale [28]. The ICC was compared between the NAT
and SUB group for all ARIA-E features. The ICC among all
raters was measured in all 75 patients for each ARIA-E find-
ing in all the six regions and both hemispheres. Concordance
was considered poor-to fair with ICCs ≤0.40; moderate with
ICC 0.41–0.60; good with ICC 0.61–0.80; and excellent with
ICC ≥0.80 [29, 30]. The diagnostic accuracy of NATand SUB
was reported in terms of sensitivity and specificity with 95 %
confidence intervals (CIs).
The inter-rater agreement, i.e. interobserver variation
among the five raters was assessed by taking into account
the overall number of ARIA-E lesions in all brain areas and
measuring the proportion of specific agreement [27]. Every
score (range 0–5) of each rater was compared to all the other
raters’ scores per subtype in each hemisphere (L/R), resulting
in ten ratings combinations within each hemisphere, which
were afterwards summed up. The specific agreement shows
the concordance among neuroradiologists with respect to the
presence of positive (presence of ARIA-E) and negative
(absence of ARIA-E) ratings. We also tested the effect on
agreement measures of increasing the ARIA-E positivity
threshold to a score ≥2 points. Statistical analyses were con-
ducted with the IBM SPSS for Windows, Version 22.0 (IBM
Corp., Armonk, NY, USA).
Results
In 16 out of 75 patients only the TE was slightly different
between the baseline and follow-up scans with a mean differ-
ence of 7.24 ms. The use of subtraction led to an increased
number of abnormal cases and areas (readings), although there
were more ‘false-positive’ cases in the SUB. This increased
detection of possible ARIA-E cases and suspected areas using
SUB might by caused either by showing additional cases or
additional lesions in positive cases. SUB were especially sen-
sitive to detect swelling (Figs. 1 and 2). The increased sensi-
tivity led to detection of additional small hyperintensities
on SUB, which were marked as ARIA-E, even though
some raters reported doubts regarding their vascular origin
(Fig. 2). The neuroradiologists reported insufficient quality
of 19 SUB, including five of the 29 cases with ARIA-E. On
the other hand, 16 SUB, 11 of which were ARIA-E posi-
tive, were marked as highly beneficial for the rating sake.
Although some discrepant readings were reported (Fig. 3),
neuroradiologists indicated that SUB were helpful in the
Table 2 Amyloid-related image abnormalities with vasogenic oedema and/or sulcal effusion (ARIA-E) rating scale
FLAIR finding Baseline scoring ARIA-E after treatment initiation Evolution of ARIA-E
Parenchymal hyperintensity ARWMC score by
1. Lesion size
2. Region and side
(if yes – ARIA-E like?)
Count new focal lesions
1. By region and side
2. By largest cross-sectional diameter
Score 0- 0
Score 1- Monofocal ≤ 2 cm
Score 2- Multifocal ≤ 2 cm
Score 3- Any lesion > 2 but < 4 cm
Score 4- Any lesion >4 cm
Score 5- Entire lobe
Increase ARIA-E
ARIA-E unchanged
Partial resolution
Full resolution
N/A initial identification
N/A other pathology
Sulcal hyperintensity Yes / No Count new focal lesions
1. By region and side
2. By largest cross-sectional diameter
Score 0- 0
Score 1- Monofocal ≤ 2 cm
Score 2- Multifocal ≤ 2 cm
Score 3- Any lesion > 2 but < 4 cm
Score 4- Any lesion >4 cm
Score 5- Entire lobe
Increase ARIA-E
ARIA-E unchanged
Partial resolution
Full resolution
N/A initial identification
N/A other pathology
Swelling Yes / No Count new focal lesions
1. By region and side
2. By largest cross-sectional diameter
Score 0-0
Score 1- Monofocal ≤ 2 cm
Score 2- Multifocal ≤ 2 cm
Score 3- Any lesion > 2 but < 4 cm
Score 4- Any lesion >4 cm
Score 5- Entire lobe
Increase ARIA-E
ARIA-E unchanged
Partial resolution
Full resolution
N/A initial identification
N/A other pathology
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detection or exclusion of ARIA-E abnormalities when im-
age quality was sufficient.
The sensitivity and specificity of NAT and SUB evalua-
tions, based on single-rater scores, are reported in Table 3A
and B. Assessing the ARIA-E positive cases using only NAT,
the detection of ARIA-E resulted in no missed ARIA-E cases
(false-negatives, FN) and two false-positives (FP). Using
SUB, one FN case and five FP cases were found (Fig. 4). In
total there were 29 ARIA-E cases and 46 non-ARIA-E cases
scored by five raters, resulting in 375 readings. The detection
of ARIA-E in all readings is shown in Table 3C and D. Using
NAT, one rater found six FN and two FP reading (score 1).
Fig. 2 Details of three cases, with
axial baseline FLAIR scan (left),
the follow-up FLAIR scan
(center) showing doubtful
amyloid-related image
abnormalities with vasogenic
oedema and/or sulcal effusion
(ARIA-E) findings and
subtraction images (right) aiding
in their detection (a), evaluation
of their extent (b), and differential
diagnosis (c). (a) Image artifacts
prevent ARIA-E detection in
FLAIR but the abnormalities are
more visible on subtraction
images. (b) The extension of the
gyral swelling in the left occipital
lobe is cumbersome to evaluate
on FLAIR images but definitely
more clear-cut in the subtraction
images. (c) Small signal
hyperintensities are visible on
both FLAIR and subtraction
images, hence their vascular
origin may be excluded
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Fig. 3 Some doubtful amyloid-related image abnormalities with
vasogenic oedema and/or sulcal effusion (ARIA-E) lesions are detected
on the left and right parietal areas (white arrows) they could not be
confirmed/excluded on the subtraction image (d) due to angulation
differences of the baseline scan (a) and the follow-up scan (b).
Although the registered baseline (c) is comparable with the follow-scan,
a typical misregistration artifact occurred (white triangle). Two out of five
neuroradiologists rated this case as a parenchymal hyperintensity ARIA-
E lesion
Table 3 The sensitivity (Sens), specificity (Spec), positive predictive value (PPV) and negative predictive value (NPV) based on a positive/negative
test (T+/T-) in ARIA cases (D+) and non-ARIA cases (D-) in (A) native images (NAT) and (B) subtraction images (SUB) if ≥1 rater scored a case with 1
or higher. In sections C and D the detection is shown in all readings of five raters in all 75 case
Eur Radiol
Using SUB, five FN (all five raters missed one case) and
seven FP readings were reported (three cases with one positive
reading, two cases with two positive readings).
When assessing the ARIA-E detection by majority vote
(i.e. a minimum of three raters gave a score of at least 1 in
one brain region), no FP or FN cases occurred in the NATand
SUB group, resulting in 100 % sensitivity and specificity. The
highest rating among all the ARIA-E characteristics per region
was selected and summed up, and the results for each neuro-
radiologist with and without the use of SUB are reported in
Fig. 4a and b, respectively. The range of scores was wider in
most cases in the SUB compared to NAT.
The ICC scores with 95 % CIs are reported in Table 4.
Overall, the ICC scores of the SUB tended to be lower com-
pared to NAT, even though no statistically significant differ-
encewas found. Excellent inter-rater agreement was measured
with the NAT and the SUB for sulcal hyperintensity, highest
score of the subtypes, and sum of sulcal hyperintensity and
gyral swelling.
The ICC of sulcal hyperintensity was excellent in the NAT
and good in the SUB. The ICC of the highest score of the three
subtypes was excellent for both modalities. The ICC of the
sum score of sulcal hyperintensity and sulcal swelling was
excellent in the NAT and good in the SUB.
Fig. 4 Sum of the scores per
rater in all cases that were rated
positively by a minimum of one
rater. The vertical axis shows the
sum of the highest scores in all
amyloid-related image
abnormalities with vasogenic
oedema and/or sulcal effusion
(ARIA-E) subtypes of all 12 brain
areas. (a) In the native image
group the horizontal axis shows
31 patients, including 29 ARIA-E
cases and two false positives
(FPs) (cases 5 and 9). (b) In the
subtraction group 33 cases are
shown, including 28 ARIA-E,
one false negative FN (case 61)
and five FPs (cases 5, 6, 9, 32 and
41)
Eur Radiol
The proportion of specific agreement of all subtypes is
shown in Table 5. The overall agreement was excellent for
both modalities in all three ARIA subtypes (range 88.8–
95.5 %). The positive agreement for sulcal hyperintensity
was good; for swelling it was good in the NAT and mod-
erate in the SUB; and for parenchymal hyperintensity was
moderate in both groups. The negative agreement was
excellent for all subtypes. Setting the cut-off level to ≥2
for a positive test result, the overall agreement remained
consistent (0.5–1.2 % increase), while the positive agree-
ment decreased in parenchymal and sulcal hyperintensity
as well as in the swelling subtype.
No relevant variations in positive and negative agree-
ment were observed when combining the abnormalities
subtypes (range -0.3 % to +1.4 %). In contrast, when
sulcal hyperintensity and sulcal swelling were combined,
the overall agreement increased to excellent in both
groups. Finally, increasing the positivity cut-off to ≥2
raters scoring ARIA-E, the positive agreement increased
to excellent.
Discussion
Amyloid-related imaging abnormalities occur in AD patients
undergoing immune therapy. In this study, we evaluated the
sensitivity, specificity, inter-rater reliability and specific posi-
tive and negative agreement among five experienced neurora-
diologists detecting and classifying ARIA-E with and without
the use of SUB. The raters used the subtraction technique in
addition to standard axial FLAIR images to identify and rate
ARIA-E. Discrepancies in ratings occurred mostly in the
presence of sulcal hyperintensities or when differentiating
small parenchymal hyperintensities from vascular lesions.
The detection of ARIA-E was high in the NAT and SUB,
but the specificity was lower using the SUB. Our results with
the use of NAT only were in line with previous studies [15].
We registered more FP cases with SUB compared to NAT (13
and two FP, respectively). The sensitivity and specificity with
NAT and SUB by majority vote was excellent. Once an
ARIA-E finding was detected, the neuroradiologists tried to
rate it as either parenchymal hyperintensity, sulcal
hyperintensity or sulcal swelling, but this categorisation was
challenging especially when distinguishing between sulcal
hyperintensity and sulcal swelling. The ICCs of sulcal
hyperintensities was excellent using the NAT (0.915) and
good (0.740) using SUB. Lower ICC scores were reported
for sulcal swelling in NATand SUB (0.660 and 0.440, respec-
tively), due to inconsistencies in raters’ interpretation of the
characteristics. Because of the lack of signal hyperintensities,
the identification of the boundaries of swelling was challeng-
ing on the NAT and likely caused variations among raters’
scores. ARIA-E rating for gyral swelling and parenchymal
hyperintensities improved when using only NAT, but, when
combining the two subtypes together, the ICC increased to
excellent in both NAT and SUB groups. The combination of
sulcal hyperintensity and gyral swelling in the ARIA-E rating
scale would therefore provide higher inter-rater reliability.
When assessing all the brain areas together for each of the
75 AD patients, the inter-rater reliability among all neuroradi-
ologists ranged between good and excellent, except for swell-
ing, for which moderate agreement was reported. Since the
total of the scores in each of the 12 regions per subtype
approached a nominal scale, the ICC statistical test was
employed to describe the scores’ variation for each
Table 4 Intra-class correlation coefficient of the five raters of the
ARIA-E imaging features in all 75 patients and in the ARIA-E cases only,
averaged by all regions in each hemisphere. As is shown, the ICC of the
subtraction group is slightly lower than the ICC of the native image
group. The ICC score in the subtraction group of PH, SH and SW ranged
from moderate to good (0.6–0.8). The combination of sulcal
hyperintensity and gyral swelling resulted in an excellent agreement (a
score above 0.8)
MRI ICC ICC
ARIA-E imaging features n=75 95 % CI n=29 95 % CI
Parenchymal hyperintensity Native 0.630 0.60-0.66 0.611 0.56-0.56
Subtraction 0.592 0.56-0.62 0.580 0.52-0.65
Sulcal hyperintensity Native 0.800 0.78-0.82 0.780 0.75-0.81
Subtraction 0.745 0.72-0.77 0.721 0.66-0.77
Swelling Native 0.683 0.66-0.71 0.634 0.58-0.69
Subtraction 0.606 0.58-0.64 0.576 0.51-0.65
Highest score of subtypes Native 0.912 0.89-0.93 0.810 0.73-0.87
Subtraction 0.823 0.81-0.84 0.824 0.79-0.86
Sulcal hyperintensity and gyral swelling Native 0.836 0.82-0.85 0.811 0.78-0.84
Subtraction 0.815 0.80-0.83 0.805 0.76-0.84
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abnormality subtype [30]. All brain regions showing no
ARIA-E abnormalities were also taken into account, which
led to reduced CIs. Among the 29 ARIA-E positive patients,
the CIs of the ICCs were wider compared to the whole set of
75 patients. Thus, in the clinical setting, summing the scores
of all abnormalities in each brain area may result in a low ICC
and hence in an imprecise lesion load estimate.
The specific agreement on each ARIA-E subtype demon-
strated no statistically significant differences with or without
the use of SUB. The positive agreement was slightly lower in
Table 5 Specific agreement amyloid-related image abnormalities with vasogenic oedema and/or sulcal effusion (ARIA-E) characteristics and
combination of sulcal hyperintensity and gyral swelling
Parietal hyperintensity Native images Subtraction images
Total n Estimate % (CI) Total n Estimate % (CI)
Overall agreement Agreement 9,000 8,591 95.5 (95.0–95.9) 9,000 8,595 95.5 (95.1–96.0)
Agreement+1 9,000 8,775 97.5 (97.2–97.8) 9,000 8,812 97.9 (97.6–98.2)
Cut-off 0 vs. ≥1 Mean agreement 9,000 8,680 96.4 (96.0–96.8) 9,000 8,694 96.6 (96.2–97.0)
Positive agreement 376 216 57.4 (52.3–62.5) 332 179 53.9 (48.4–59.4)
Negative agreement 8,624 8,464 98.4 (97.8–98.4) 8,668 8,515 98.2 (97.9–98.5)
Cut-off 0–1 vs. ≥2 Mean agreement 9,000 8,764 97.4 (97.0–97.7) 9,000 8,798 97.8 (97.4–98.1)
Positive agreement 262 144 55.0 (48.7–61.1) 218 117 53.7 (46.8–60.4)
Negative agreement 8,738 8,620 98.6 (98.4–98.9) 8,782 8,681 98.9 (98.6–99.1)
Sulcal hyperintensity Native images Subtraction images
Total n Estimate % (CI) Total N Estimate % (CI)
Overall agreement Agreement 9,000 8,362 92.9(92.4–93.4) 9,000 8,105 90.1 (89.4–90.7)
Agreement+1 9,000 8,693 96.6 (96.2–97.0) 9,000 8,503 94.5 (94.0–94.9)
Cut-off 0 vs. ≥1 Mean agreement 9,000 8,678 96.4 (96.0–96.8) 9,000 8,500 94.4 (94.0–94.9)
Positive agreement 758 597 78.8 (75.7–81.6) 932 682 73.2 (70.2–76.0)
Negative agreement 8,242 8,081 98.0 (97.7–98.3) 8,068 7,818 96.9 (96.5–97.3)
Cut-off 0–1 vs. ≥2 Mean agreement 9,000 8,718 96.9 (96.5–97.2) 9,000 8,568 95.2 (94.7–95.6)
Positive agreement 644 503 78.1 (74.7–81.2) 820 604 73.7 (70.5–76.6)
Negative agreement 8,356 8,215 98.3 (98.0–98.6) 8,180 7,964 97.4 (97.0–97.7)
Gyral swelling Native images Subtraction images
Total n Estimate % (CI) Total n Estimate % (CI)
Overall agreement Agreement 9,000 8,247 91.6 (91.0–92.2) 9,000 7,989 88.8 (88.1–89.4)
Agreement+1 9,000 8,532 94.7 (94.2–95.2) 9,000 8,338 92.6 (92.1–93.2)
Cut-off 0 vs. ≥1 Mean agreement 9,000 8,502 94.5 (94.0–94.9) 9,000 8,295 92.2 (91.6–92.7)
Positive agreement 788 539 68.4 (65.0–71.6) 902 549 60.9 (57.6–64.1)
Negative agreement 8,212 7,963 97.0 (96.6–97.3) 8,099 7,746 95.6 (95.2–96.1)
Cut-off 0–1 vs. ≥2 Mean agreement 9,000 8,550 95.0 (94.5–95.4) 9,000 8,374 93.0 (92.5–93.6)
Positive agreement 718 493 68.7 (65.1–72.0) 808 495 61.3 (57.8–64.6)
Negative agreement 8,282 8,057 97.3 (96.9–97.6) 8,192 7,879 96.2 (95.7–96.6)
Combination sulcal hyperintensity and gyral swelling Native images Subtraction images
Total n Estimate % (CI) Total N Estimate % (CI)
Overall agreement Agreement 9,000 8,279 92.0 (91.4–92.5) 9,000 8,027 89.2 (88.5–89.5)
Agreement+1 9,000 8,668 96.3 (95.9–96.7) 9,000 8,547 95.0 (94.5–95.4)
Cut-off 0 vs. ≥1 Mean agreement 9,000 8,670 96.3 (95.9–96.7) 9,000 8,550 95.5 (94.2–95.4)
Positive agreement 968 803 83.0 (80.4–85.3) 1,158 933 80.6 (78.2–82.8)
Negative agreement 8,032 7,867 98.0 (97.6–98.2) 7,842 7,617 97.1 (96.7–97.5)
Cut-off 0–1 vs. ≥2 Mean agreement 9,000 8,690 96.6 (96.2–96.9) 9,000 8,608 96.5 (96.2–96.7)
Positive agreement 844 689 81.6 (78.9–84.2) 1,628 721 69.5 (66.6–72.3)
Negative agreement 8,156 8,001 98.1 (97.8–98.4) 7,372 7,762 97.5 (97.2–97.9)
*n= Sum of points where raters had an agreement on
**Agreement + 1 = Overall agreement of the raters including positive and negative agreement. For theseis results a cut-off ≥>=2 was chosen, therefore
scores of 0 and 1 were considered as an absence of an ARIA-E
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the subtraction group, but the performance of this test in-
creased with respect to the ICC when summing all the brain
areas. The total number of lesions rated as parenchymal
hyperintensities was three times lower than the number of
lesions rated as sulcal hyperintensities or gyral swelling.
These two latter subtypes also showed higher positive agree-
ment, probably thanks to extra information provided by the
SUB. On the other hand, their use also increased the ambigu-
ity in choosing between them, even though the total amount of
ARIA-E lesions detected remained unchanged.
When the cut-off level for positive agreement was set to a
score ≥1, a greater number of ARIA-E parenchymal
hyperintensities was detected with NAT instead of with the
SUB. No statistically significant changes were reported for
overall agreement with a cut-off level ≥2 for a positive test.
Placing a higher cut-off was an attempt to filter out small am-
biguous lesions due to artefacts. Nevertheless, this did not result
in an alteration in the value of positive agreement. Combining
sulcal hyperintensity and swelling subtypes, the positive agree-
ment increased from good to excellent in both the NAT and
SUB groups, since categorisation was not necessary anymore
and hence a more uniform rating was obtained.
We think that the quality of the FLAIR images was a major
factor influencing the raters’ agreement in both the native and
subtraction groups. A high rate of FP was detected when using
SUB due to large slice thickness resulting in subtraction arte-
facts, which had some aspect similar to an ARIA-E lesion.
This similarity caused difficulties distinguishing between ar-
tefacts and a possible ARIA-E findings.While it was expected
that the inter-rater reliability would have been slightly lower
with SUB as compared to NAT because of their methodolog-
ical similarity, it could have been possible that the FP detected
with SUB were actually ARIA-E lesions missed by the gold
standard read. However not all raters agreed on this point.
The acquisition protocols differed among the acquisition
centres, resulting in differences between patients in TR/TE,
flip-angle, voxel size, acquisition matrix, field of view and im-
age contrast. This could have led to differences in the incidence
or contrast of (pulsation) artefacts and, in some cases, suitability
for registration, since the same global scaling and registration
algorithms were used in all cases. The use of isotropic 3D-
FLAIR is likely to improve not only the detection and charac-
terisation of cortical lesions, but also SUB performance, as
shown for multiple sclerosis [31–33] thanks to higher spatial
resolution signal-to-noise ratio compared with 2D multislice
acquisition, and decreased pulsation artefacts [34].
Even though the acquisition protocol was identical within
patients, variations among centres might have deleterious ef-
fects on accuracy in registration. In addition, slice reposi-
tioning differences could have caused suboptimal co-registra-
tion. Moreover, misregistration could be due to non-linear
deformations (e.g. swelling side-effects of the immunisation
treatment) for which an elastic deformation (FNIRT)
algorithm could be considered instead of FLIRT. However,
FNIRT would countervail important ARIA-E findings’ char-
acteristics and nullify valuable aspects of swelling or sulcal
hyperintensity. Furthermore, most of the suboptimal SUB
were reported in non-ARIA cases and showed linear artefacts
in a pattern of black and white lines.
Inter-rater reliability and agreement for ARIA-E monitoring
may be improved through radiologists’ training or through a
semi-quantitative rating scale such as the one used in this study,
including all ARIA-E subtypes. A severity scale for each brain
region, would allow for monitoring on a higher level.
Conclusion
Subtraction MRI has potential as a visual aid increasing the
sensitivity of ARIA-E assessment. However, in order to im-
prove its usefulness isotropic acquisition and enhanced train-
ing are required. The ARIA-E rating scale may benefit from
combining sulcal hyperintensity and swelling.
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Study subjects or cohorts overlap Some study subjects or cohorts
have been previously reported in BA phase 2 multiple ascending dose
trial of bapineuzumab in mild to moderate Alzheimer’s disease^
(Neurology 2009;73:2061–70); BAmyloid-related imaging abnormalities
in patients with Alzheimer’s disease treated with bapineuzumab: a retro-
spective analysis^ (Lancet Neurology 2012;11:241–49); and BValidation
of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities^ (J
Neuroimaging 2017;00:1-8).
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The phase II trial included 234 patients, of whom 2,572 (FLAIR)MRI
scans were analysed in the retrospective analysis. To validate the MRI
rating scale for amyloid-related imaging abnormalities, MRI scans of 75
AD patients were analysed.
In the present study we validated and evaluated the rating scale by
analysing MRI scans of 75 AD patients with and without the addition of
the subtraction technique and complement statistical tests to measure the
agreement among multiple raters.
Methodology
• prospective
• diagnostic or prognostic study
• multicentre study
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